TREATMENT OF RELAPSED, REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA

Código QR

TREATMENT OF RELAPSED, REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA

Guardado en:

Detalles Bibliográficos
Autores principales:	Ebru Pekgüç, Burhan Ferhanoğlu
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/769556d6bb814e589b2e8127140082fe
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
por: Julio Delgado, et al.
Publicado: (2021)

Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
por: Illidge T, et al.
Publicado: (2012)

Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future
por: Flowers CR, et al.
Publicado: (2012)

Immune targeted therapy for diffuse large B cell lymphoma
por: Yaxin Zheng, et al.
Publicado: (2021)

Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
por: Gupta VA, et al.
Publicado: (2013)

A CASE OF STAGE 1E DIFFUSE LARGE B-CELL LYMPHOMA PRESENTED WITH KNEE INVOLVEMENT
por: Mesut Tığlıoğlu, et al.
Publicado: (2021)

Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase
por: Farina F, et al.
Publicado: (2014)

Intrasinusoidal Hodgkin Lymphoma; A Mimic of Anaplastic Large Cell Lymphoma
por: John R. Krause, et al.
Publicado: (2021)

Gemtuzumab ozogamicin is efficacious in attaining complete remission in relapsed/refractory acute leukemia prior to hematopoietic cell transplant: A case series
por: Giancarlo Fatobene, et al.
Publicado: (2021)

MicroRNAs as B-cell lymphoma biomarkers
por: Manterola L, et al.
Publicado: (2015)

Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma
por: Yoshimitsu M, et al.
Publicado: (2014)

The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma
por: Eko A. Pangarsa, et al.
Publicado: (2021)

MEDICAL TREATMENT IN HODGKIN LYMPHOMA
por: Nilgun Kurucu
Publicado: (2021)

MicroRNA dysregulation in B-cell non-Hodgkin lymphoma
por: Lim EL, et al.
Publicado: (2013)

Primary dural high grade B cell lymphoma mimicking subdural hematoma
por: Aya Nakaya, et al.
Publicado: (2021)

Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
por: McKinney MS, et al.
Publicado: (2014)

Trends in the treatment of cutaneous T-cell lymphoma &ndash; critical evaluation and perspectives on vorinostat
por: Zhang CL, et al.
Publicado: (2012)

Reduced intensity treatment in early-stage Hodgkin&rsquo;s lymphoma
por: Armitage JO, et al.
Publicado: (2011)

Peripheral T cell lymphoma: clinical utility of romidepsin
por: Sawey K, et al.
Publicado: (2012)

mTOR inhibitor in the treatment of Hodgkin&rsquo;s lymphoma: a case report
por: Provencio M., et al.
Publicado: (2011)

UPSHOTS IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: ANALYSIS OF T-CELL BRAZIL PROJECT
por: Carlos CHIATTONE, et al.
Publicado: (2021)

Emerging role of SOX11 in mantle cell lymphoma
por: Kuci V, et al.
Publicado: (2015)

A RARE CASE: POSTTRANSPLANT NK/T CELL LYMPHOMA
por: Pınar Tığlıoğlu, et al.
Publicado: (2021)

Advances in the diagnosis and management of lymphoma
por: Matasar MJ, et al.
Publicado: (2012)

THE SMALLEST PRIMARY BONE LYMPHOMA
por: Fatma Burçin KURTİPEK, et al.
Publicado: (2021)

A CASE OF REFRACTORY IMMUNE THROMBOCYTOPENIA APPLIED WITH AUTOLOGOUS HEMATOPOETIC STEM CELL TRANSPLANTATION
por: Mine KARADENIZ, et al.
Publicado: (2021)

Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment
por: Pujals A, et al.
Publicado: (2015)

Monomorphic epitheliotropic intestinal T-cell lymphoma of the duodenum: an aggressive disease
por: Ganesh Kasinathan
Publicado: (2021)

MYC as therapeutic target in leukemia and lymphoma
por: Cortiguera MG, et al.
Publicado: (2015)

ANTICARDIOLIPINIC ANTIBODIES IN NON-HODGKIN LYMPHOMA
por: Sanda Buruiana, et al.
Publicado: (2021)

IMMUNE THROMBOCYTOPENIA RELAPSE POST COVID-19 VACCINE IN YOUNG MALE PATIENT
por: Hana Qasim
Publicado: (2021)

Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations
por: Bodiford A, et al.
Publicado: (2015)

Preserving fertility in young patients with lymphoma: an overview
por: Patel B, et al.
Publicado: (2014)

THREE CASES WITH BURKITT LYMPHOMA PRESENTING WITH CHOLESTASIS
por: Fatma Tuba YILDIRIM, et al.
Publicado: (2021)

CASE REPORT: FOLLICULAR LYMPHOMA PRESENTED WITH CHYLOTHORAX
por: Senem MARAL, et al.
Publicado: (2021)

A CASE OF MULTI REGIONAL PRIMARY MUSCLE LYMPHOMA
por: Beyza OLUK, et al.
Publicado: (2021)

Emerging targets in human lymphoma: targeting the MYD88 mutation
por: Wang JQ, et al.
Publicado: (2013)

BURKITT LYMPHOMA PRESENTING WITH EYE AND KIDNEY INVOLVEMENT: CASE REPORT
por: Aslı Turgutoğlu Yılmaz, et al.
Publicado: (2021)

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS
por: Mehmut TURGUT, et al.
Publicado: (2021)

PROGNOSIS FACTORS IN AGGRESSIVE NON-HODGKIN LYMPHOMAS WITH PRIMARY INVOLVEMENT OF THE SPLEEN
por: Larisa Musteata, et al.
Publicado: (2021)